Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anouk E Muller

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Drugs|February 25, 2018
Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?Anouk E Muller, Benedikt Huttner, Angela Huttner
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumoniaAnouk E Muller, Nieko Punt, Johan W Mouton
Antibiotics (Basel, Switzerland)|August 26, 2023
Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric ConsiderationsAnouk E Muller, Peter van Vliet, Birgit C P Koch
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2020
[Nitrofurantoin for uncomplicated urinary tract infections in men: should it be the first choice?]Tim J A Dekker, Anouk E Muller, Luc B S Gelinck
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 5, 2019
Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?Rixt A Wijma, Fiona Fransen, Anouk E Muller, et al.
Expert Opinion on Pharmacotherapy|November 1, 2016
Ceftazidime-avibactam for the treatment of complicated intra-abdominal infectionsSara A Buckman, Tamara Krekel, Anouk E Muller, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2013
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation studyAnouk E Muller, Anne H Schmitt-Hoffmann, Nieko Punt, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2024
Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individualsAnouk E Muller, Brenda C M De Winter, Birgit C P Koch
Acta Obstetricia Et Gynecologica Scandinavica|August 25, 2006
Morbidity related to maternal group B streptococcal infectionsAnouk E Muller, Paul M Oostvogel, Eric A P Steegers, et al.
International Journal of Antimicrobial Agents|March 7, 2017
Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: how short can it be and are the results accurate?Wouter van den Bijllaardt, Anton G Buiting, Johan W Mouton, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Drugs|February 25, 2018
Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?Anouk E Muller, Benedikt Huttner, Angela Huttner
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumoniaAnouk E Muller, Nieko Punt, Johan W Mouton
Antibiotics (Basel, Switzerland)|August 26, 2023
Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric ConsiderationsAnouk E Muller, Peter van Vliet, Birgit C P Koch
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2020
[Nitrofurantoin for uncomplicated urinary tract infections in men: should it be the first choice?]Tim J A Dekker, Anouk E Muller, Luc B S Gelinck
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 5, 2019
Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?Rixt A Wijma, Fiona Fransen, Anouk E Muller, et al.
Expert Opinion on Pharmacotherapy|November 1, 2016
Ceftazidime-avibactam for the treatment of complicated intra-abdominal infectionsSara A Buckman, Tamara Krekel, Anouk E Muller, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2013
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation studyAnouk E Muller, Anne H Schmitt-Hoffmann, Nieko Punt, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2024
Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individualsAnouk E Muller, Brenda C M De Winter, Birgit C P Koch
Acta Obstetricia Et Gynecologica Scandinavica|August 25, 2006
Morbidity related to maternal group B streptococcal infectionsAnouk E Muller, Paul M Oostvogel, Eric A P Steegers, et al.
International Journal of Antimicrobial Agents|March 7, 2017
Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: how short can it be and are the results accurate?Wouter van den Bijllaardt, Anton G Buiting, Johan W Mouton, et al.
Pageof 7